Athira Pharma, Inc. (ATHA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Mark J. Litton
Employees:
40
4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE, WA 981952141
5095927191

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in Phase 3 and ACT-AD clinical trials for the treatment of Alzheimer's disease.

Data derived from most recent annual or quarterly report
Market Cap 121.564 Million Shares Outstanding37.636 Million Avg 30-day Volume 266.452 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.63
Price to Revenue0.0 Debt to Equity0.0 EBITDA-82.52 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value0
Current Ratio26.399 EPS Growth-0.875 Quick Ratio26.043
1 Yr BETA 1.2277 52-week High/Low 16.65 / 2.53 Profit Margin0.0
Operating Cash Flow Growth-83.4054 Altman Z-Score0.0 Free Cash Flow to Firm -55.769 Million
Earnings Report2022-11-09
View SEC Filings from ATHA instead.

View recent insider trading info

Athira Pharma, Inc. YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ATHA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ATHA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2022-07-01 by EDELMAN JOSEPH
  • 4: filed on 2022-06-30 by MOEBIUS HANS
  • 4: filed on 2022-06-24 by WORTHINGTON MARK
  • 4: filed on 2022-06-24 by MOEBIUS HANS
  • 4: filed on 2022-06-24 by MILESON GLENNA
  • 4: filed on 2022-06-24 by LITTON MARK JAMES
  • 4: filed on 2022-06-24 by LENINGTON RACHEL
  • 4: filed on 2022-06-24 by CHURCH KEVIN
  • 4: filed on 2022-06-10 by CHURCH KEVIN
  • 4: filed on 2022-05-27 by PICKERING GRANT

    • Events (8k)

  • 8-K: filed on 2022-08-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-22:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-24:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-24:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-10-21:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-09:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-06-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    EDELMAN JOSEPH

    • Director
    • 10% Owner
    		 4,797,278 2022-06-29 2

    MOEBIUS HANS CHIEF MEDICAL OFFICER

    • Officer
    		 52,955 2022-06-28 3

    LITTON MARK JAMES CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 148,244 2022-06-22 2

    MILESON GLENNA CHIEF FINANCIAL OFFICER

    • Officer
    		 109,167 2022-06-22 4

    CHURCH KEVIN EXECUTIVE VP, RESEARCH

    • Officer
    		 57,695 2022-06-22 4

    LENINGTON RACHEL CHIEF OPERATING OFFICER

    • Officer
    		 5,807 2022-06-22 3

    WORTHINGTON MARK GENERAL COUNSEL

    • Officer
    		 19,097 2022-06-22 3

    EDELMAN JOSEPH

    • Director
    		 13,871 2022-05-20 2

    FLUKE JOHN M JR

    • Director
    		 13,871 2022-05-20 1

    PERCEPTIVE ADVISORS LLC

    PERCEPTIVE LIFE SCIENCES MASTER FUND LTD

    • Director
    • 10% Owner
    		 13,871 2022-05-20 1

    JOHNSON JAMES A

    • Director
    		 13,871 2022-05-20 1

    PICKERING GRANT

    • Director
    		 3,467 2022-05-20 4

    PANZARA MICHAEL A.

    • Director
    		 2,311 2022-05-20 3

    ROMANO KELLY A

    • Director
    		 13,871 2022-05-20 2

    KOSACZ BARBARA

    • Director
    		 13,871 2022-05-20 1

    YAMADA TADATAKA

    • Director
    		 13,871 2021-05-28 0

    KAWAS LEEN PRESIDENT & CEO

    • Officer
    • Director
    		 231,000 2021-02-18 0

    RTW INVESTMENTS, LP

    WONG RODERICK

    • 10% Owner
    		 No longer subject to file 2020-09-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ATHIRA PHARMA INC ATHA 2022-09-08 15:15:04 UTC 1.7008 0.6192 1300000
    ATHIRA PHARMA INC ATHA 2022-09-08 14:45:03 UTC 1.7008 0.6192 1300000
    ATHIRA PHARMA INC ATHA 2022-09-08 14:15:03 UTC 1.7008 0.6192 1300000
    ATHIRA PHARMA INC ATHA 2022-09-08 13:45:03 UTC 1.7008 0.6192 1300000
    ATHIRA PHARMA INC ATHA 2022-09-08 13:15:03 UTC 1.7008 0.6192 1300000
    ATHIRA PHARMA INC ATHA 2022-09-08 12:45:03 UTC 1.7008 0.6192 1300000
    ATHIRA PHARMA INC ATHA 2022-09-07 22:15:05 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 21:45:05 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 21:15:04 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 20:45:03 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 20:15:05 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 19:45:04 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 19:15:04 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 18:45:04 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 18:15:05 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 17:45:04 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 17:15:05 UTC 1.7008 0.6192 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 16:45:04 UTC 1.7188 0.6012 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 16:15:04 UTC 1.7188 0.6012 1400000
    ATHIRA PHARMA INC ATHA 2022-09-07 15:45:04 UTC 1.7188 0.6012 1400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund ATHA -592.0 shares, $-6091.68 2022-04-30 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund ATHA -1764.0 shares, $-5380.2 2022-06-30 N-PORT

    Elevate your investments